PepSets™ Peptide Libraries ❭

PepSets™ can be supplied with a precise length and offset designed to best suit the user’s assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence to adapt the usage for any experimental purpose.

In recent years, PepSets™ have had tremendous successes in the immunology sector for vaccine and drug development. These versatile molecular tools have further applications in dozens of fields, including epitope mapping and structure-activity studies.  

  • Discover crucial residues with an Alanine Scan Library 
  • Map epitopes with an Overlapping Peptide Library 
  • Narrow down the shortest active sequences with a Truncated Peptide Library

Fast & Reliable

Mimotopes is the founder of peptide libraries. Across the 35 years since its inception, the technology and its userbase have developed side-by-side to make PepSets™ an unrivaled juggernaut in research today.

Hundreds of peptides are synthesized simultaneously with Mimotopes’ exclusive parallel synthesis technology. Thanks to a rapid production cycle, peptide libraries reach their users fast, aiming to never delay critical experiments.

Contact us today for a quote!

Australia

☎ +61 3 9565 1111
✉ australia@mimotopes.com

North and South America

☎ +1 651 603 0909
✉ useast@mimotopes.com
uswest@mimotopes.com

Asia

☎ +61 3 9565 1111
✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547
✉ europe@mimotopes.com

Go to article: Home | Biotechs surf obesity drug wave to go beyond GLP-1RAsGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Bio Image SystemsGo to article: phasetwoGo to article: In DepthGo to article: Biotechs surf obesity drug wave to go beyond GLP-1RAsGo to article: The opioid crisis: Different delivery systems tackle treatment needs Go to article: Pharma readies for climate disasters amidst supply chain concernsGo to article: CRISPR pipeline accelerates after milestone Casgevy approvalGo to article: The future of cell and gene therapy manufacturingGo to article: Amgen showcases exciting potential in the obesity space at JPM24 Go to article: Q&A: Regulatory reform necessary to improve obesity drug accessGo to article: Novo to buy Catalent: The backlash beginsGo to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue